Ezetimibe: Effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease [2]

Expert Opinion on Drug Safety

Volumn 5, Issue 4, 2006, Pages 487-488

  Ahmed, Mohamed H ^a   Saad, Rasheed A ^a   Osman, Meissa M ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOCHEMICAL MARKER; CYTOCHROME P450; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL;

CHOLESTEROL METABOLISM; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERANCE; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LETTER; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PREVALENCE; PROTEIN EXPRESSION; STEATOSIS; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG COMBINATIONS; DYSLIPIDEMIAS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; SIMVASTATIN;

EID: 33749121807     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.4.487     Document Type: Letter

References (7)

1. TOTH PP, DAVIDSON MH: Simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Phamacother. (2005) 6(1):131-139.
2. AHMED MH, BYRNE CD: Non-alcoholic steatoheptatitis. In: Metabolic syndrome, Byrne CD, Wild S (Eds) Wiley & Sons, Chichester, UK (2005):279-303.
3. AHMED MH: The dilemma of invasive and non-invasive investigations for adult and paediatric non-alcoholic fatty liver disease: has the time come for a new biochemical marker? Clin. Chem. Lab. Med. (2006) 44(4):508-509.
4. KNOPP RH, DUJOVNE CA, LE BEAUT A et al.: Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled Phase III clinical studies. Int. J. Clin. Pract. (2003) 57(5):363-368.
5. SIMONS L, TONKON M, MASANA L et al.: Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr. Med. Res. Opin. (2004) 20(9):1437-1445.
6. ALTMANN SW, DAVIS HR Jr. ZHU LJ et al.: Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 303(5661):1201-1204.
7. DAVIES JP, SCOTT C, OISHI K et al.: Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. (2005) 280(13):12710-12720.